Fidelis Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.57M | Sell |
28,374
-145
| -0.5% | -$28.5K | 0.51% | 38 |
|
|
2025
Q1 | $5.31M | Buy |
28,519
+1,560
| +6% | +$290K | 0.56% | 35 |
|
|
2024
Q4 | $5.13M | Buy |
26,959
+2,214
| +9% | +$421K | 0.51% | 39 |
|
|
2024
Q3 | $4.65M | Buy |
24,745
+1,778
| +8% | +$334K | 0.55% | 35 |
|
|
2024
Q2 | $4.31M | Buy |
22,967
+2,347
| +11% | +$440K | 0.61% | 32 |
|
|
2024
Q1 | $3.75M | Buy |
20,620
+4,456
| +28% | +$811K | 0.57% | 35 |
|
|
2023
Q4 | $2.5M | Buy |
16,164
+2,607
| +19% | +$404K | 0.55% | 36 |
|
|
2023
Q3 | $2.02M | Buy |
13,557
+2,187
| +19% | +$326K | 0.69% | 31 |
|
|
2023
Q2 | $1.53M | Buy |
11,370
+678
| +6% | +$91.3K | 0.56% | 41 |
|
|
2023
Q1 | $1.58M | Buy |
10,692
+7,602
| +246% | +$1.13M | 0.67% | 35 |
|
|
2022
Q4 | $500K | Buy |
+3,090
| New | +$500K | 0.59% | 58 |
|